Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, Bristol-Myers Squibb to Deploy Liquid Biopsies in Clinical Trials

NEW YORK (GenomeWeb) – Guardant Health said today that it is working with Bristol-Myers Squibb to develop the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.

Redwood City, California-based Guardant has struck similar partnerships with AstraZeneca, Merck, Merck KGaA, and Pfizer.

GuardantOMNI is designed to help investigators screen patients for multiple clinical trial options using a simple blood draw to enable real-time monitoring of tumor response and tumor evolution, and to support analysis of tumor mutational burden for use with immunotherapy trials, Guardant said.

"Our agreement with Guardant Health will allow us to further explore genomic biomarkers as we advance our clinical-stage pipeline," Bruce Car, head of translational sciences at Bristol-Myers Squibb, said in a statement. "Non-invasive methods of acquiring tumor DNA will provide more data, potentially leading to greater insights into patient response."